Clinical trial · Observational
E²-RADIatE: EORTC-ESTRO RADiotherapy InfrAstrucTure for Europe
NCT03818503CI-TRIAL-00087546E²-RADIatErecruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The primary objective is the collection of real-world data of cancer patients treated with radiotherapy, to support radiotherapy research and to provide evidence of the role of radiation oncology in a multidisciplinary approach. This is an open ended prospective non-interventional non-therapeutic multi-cohort study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- OligoCare
- description
- Patients with oligometastatic disease treated with radical radiotherapy
- label
- ReCare
- description
- Patients treated with high-dose Re-irradiation
Primary outcomes (1)
- measure
- Number of patients treated with radiotherapy enrolled in the program
- timeFrame
- 5 years
Secondary outcomes (5)
- measure
- Disease free survival
- timeFrame
- 5 years
- measure
- Loco-regional control
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 12 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically confirmed cancer. * Written informed consent for E²-RADIatE according to applicable legal and ethical requirements * Planned use of radiotherapy * Eligibility of the patient confirmed for at least one cohort confirmed * Patients of 12 years and older
References
Publications (2)
- DERIVEDChrist SM, Alongi F, Ricardi U, Scorsetti M, Livi L, Balermpas P, Lievens Y, Braam P, Jereczek-Fossa BA, Stellamans K, Ratosa I, Widder J, Peulen H, Dirix P, Bral S, Ramella S, Hemmatazad H, Khanfir K, Geets X, Jeene P, Zilli T, Fournier B, Ivaldi GB, Clementel E, Fortpied C, Oppong FB, Ost P, Guckenberger M. Cancer-specific dose and fractionation schedules in stereotactic body radiotherapy for oligometastatic disease: An interim analysis of the EORTC-ESTRO E2-RADIatE OligoCare study. Radiother Oncol. 2024 Jun;195:110235. doi: 10.1016/j.radonc.2024.110235. Epub 2024 Mar 19. PMID 38508239
- DERIVEDNieder C, Willmann J, Andratschke NH. Prospective randomized clinical studies involving reirradiation: update of a systematic review. Strahlenther Onkol. 2023 Sep;199(9):787-797. doi: 10.1007/s00066-023-02118-1. Epub 2023 Jul 27. PMID 37500926